SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) released its earnings results on Tuesday. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15), FiscalAI reports.
Here are the key takeaways from SAB Biotherapeutics’ conference call:
- SABBio said SAFEGUARD enrollment is on track, with Part A fully enrolled and Part B now actively enrolling across the U.S., Australia, New Zealand, the U.K. and Europe.
- The company received FDA written confirmation that C-peptide may be used as a surrogate endpoint for accelerated approval, which management described as a meaningful de-risking of the regulatory path.
- Phase I SAB-142 data continued to support the program, with management highlighting beta-cell preservation, T-cell exhaustion, and a favorable safety profile including no serum sickness and low or no immunogenicity.
- SABBio ended Q1 with $217.6 million in cash, cash equivalents and available-for-sale securities, which it says funds operations through 2028 and supports SAFEGUARD plus pre-commercial work.
- The company also signed a multi-year manufacturing agreement with Emergent BioSolutions to support process development and both clinical and commercial production ahead of a potential launch.
SAB Biotherapeutics Trading Down 4.3%
Shares of SABS stock traded down $0.16 during trading hours on Tuesday, reaching $3.56. 560,084 shares of the stock traded hands, compared to its average volume of 648,684. SAB Biotherapeutics has a 1-year low of $1.60 and a 1-year high of $6.60. The business has a fifty day moving average price of $3.87 and a 200 day moving average price of $3.81. The company has a quick ratio of 9.46, a current ratio of 9.46 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $181.38 million, a PE ratio of -1.53 and a beta of 0.55.
Institutional Investors Weigh In On SAB Biotherapeutics
Wall Street Analysts Forecast Growth
SABS has been the topic of a number of research reports. Rodman & Renshaw reiterated a “buy” rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a report on Monday. Weiss Ratings restated a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Friday, April 10th. Zacks Research lowered shares of SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, March 12th. Chardan Capital boosted their price target on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Finally, Wall Street Zen lowered shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $10.50.
View Our Latest Analysis on SABS
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.
The company’s lead programs are directed primarily at infectious diseases.
Read More
- Five stocks we like better than SAB Biotherapeutics
- Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?
- Shake Shack Stock Gets Shaken After Earnings Miss
- On Holdings Sets Up for Marathon Rally: New Highs Are Coming
- The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
